CRC
Oncology · 2005–2024
22decisions
8medicines
6carried consumer input
13individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| bevacizumab Multiple cancer indications: metastatic colorectal cancer, locally recurrent or metastatic breast cancer, advanced/metastatic/recurrent non-squamous non-small… | Mar 2024 | Recommended | 1 individuals Medical Oncology Group |
| encorafenib Treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E variant who have received prior systemic therapy, in combination with an… | May 2021 | Deferred | 1 individuals Bowel Cancer Australia · Rare Cancers Australia · Medical Oncology Group |
| encorafenib Treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E variant who have received prior systemic therapy, in combination with an… | Mar 2021 | Deferred | 1 individuals Bowel Cancer Australia · Rare Cancers Australia · Medical Oncology Group |
| pembrolizumab First-line treatment of unresectable or metastatic (Stage IV) mismatch repair deficient (dMMR) colorectal cancer in patients who have not previously received… | Mar 2021 | Recommended with restriction | 9 individuals Medical Oncology Group |
| bevacizumab Biosimilar to Avastin; indicated for the same indications as the reference bevacizumab (includes first-line treatment of Stage IV non-squamous non-small cell… | Nov 2021 | Recommended with restriction | unclear |
| trifluridine with tipiracil Treatment of patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies… | Mar 2018 | Not recommended | input received Bowel Cancer Australia · Medical Oncology Group |
| panitumumab First-line treatment of RAS wild-type metastatic colorectal cancer in combination with oxaliplatin-based chemotherapy. | Mar 2015 | Recommended | no section in document |
| regorafenib Initial or continuing treatment of metastatic colorectal cancer following failure of, or intolerance to, other treatment options (fluoropyrimidine-,… | Jul 2014 | Recommended with restriction | 1 individuals |
| panitumumab Treatment of K-RAS wild-type metastatic colorectal cancer as monotherapy or in combination with FOLFIRI after failure of first-line chemotherapy, and in… | Mar 2013 | Not recommended | no section in document |
| panitumumab Treatment of K-RAS wild-type metastatic colorectal cancer in patients who have failed first-line chemotherapy, for use as monotherapy or in combination with… | Nov 2013 | Recommended with restriction | no section in document |
| capecitabine Adjuvant treatment of stage III (Dukes C) colon cancer following complete resection of the primary tumour, either as monotherapy or in combination with… | Mar 2011 | Recommended with restriction | no section in document |
| capecitabine Adjuvant treatment of stage III (Dukes C) colon cancer following complete resection of the primary tumour, either as monotherapy or in combination with… | Mar 2011 | Recommended with restriction | no section in document |
| cetuximab Treatment of patients with K-RAS wild-type metastatic colorectal cancer as monotherapy or in combination with irinotecan-based chemotherapy following failure… | Jul 2010 | Recommended with restriction | no section in document |
| cetuximab Treatment of patients with K-RAS wild-type metastatic colorectal cancer as monotherapy or in combination with irinotecan-based chemotherapy following failure… | Jul 2010 | Recommended with restriction | no section in document |
| cetuximab Treatment of patients with metastatic colorectal cancer with KRAS wild-type tumours who have failed 5-fluorouracil or capecitabine, failed irinotecan-based… | Mar 2009 | Not recommended | no section in document |
| bevacizumab Initial treatment of metastatic colorectal cancer in previously untreated patients in combination with first-line chemotherapy. | Jul 2008 | Recommended with restriction | no section in document |
| bevacizumab Treatment of metastatic colorectal cancer in previously untreated patients (WHO performance status 0 or 1) in combination with 5-fluorouracil and folinic acid,… | Mar 2008 | Not recommended | no section in document |
| cetuximab Treatment of patients with metastatic colorectal cancer who have failed irinotecan-based therapy and either failed or are unsuitable for oxaliplatin-based… | Nov 2008 | Not recommended | no section in document |
| panitumumab Treatment of K-RAS wild-type metastatic colorectal cancer after failure of fluoropyrimidine, irinotecan, and oxaliplatin-based chemotherapy. | Nov 2008 | Recommended | no section in document |
| capecitabine Adjuvant treatment of patients with Dukes' C colon cancer following complete resection of the primary tumour. | Nov 2005 | Recommended with restriction | no section in document |
| capecitabine Adjuvant treatment of patients with Dukes' C colon cancer following complete resection of the primary tumour. | Nov 2005 | Recommended with restriction | no section in document |
| cetuximab Treatment of metastatic colorectal cancer (MCRC) in patients with EGFR-positive disease whose disease has progressed or is refractory to irinotecan-based… | Nov 2005 | Not recommended | no section in document |
Who spoke
Medical Oncology Group · Bowel Cancer Australia · Rare Cancers Australia
What the PBS pays
$942M in government benefit over 2024–25, across 314,334 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| pembrolizumab | $739.6M |
| Bevacizumab | $49.4M |
| bevacizumab | $49.4M |
| cetuximab | $42.5M |
| encorafenib | $37.7M |
| panitumumab | $12.8M |
| trifluridine with tipiracil | $9.8M |
| capecitabine | $1M |
Appraised elsewhere
NICE, in England and Wales, has appraised 15 technologies for this condition, recommending 12 and declining 2. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| bevacizumabBevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer | TA1136 | recommended | 2026-02 |
| fruquintinibFruquintinib for previously treated metastatic colorectal cancer | TA1079 | recommended | 2025-07 |
| nivolumab plus ipilimumabNivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA1065 | recommended restricted | 2025-05 |
| trifluridine tipiracilTrifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments | TA1008 | recommended restricted | 2024-09 |
| regorafenibRegorafenib for previously treated metastatic colorectal cancer | TA866 | recommended restricted | 2023-02 |
| nivolumabNivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA716 | recommended restricted | 2021-07 |
| pembrolizumabPembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA709 | recommended restricted | 2021-06 |
| encorafenib plus cetuximabEncorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer | TA668 | recommended restricted | 2021-01 |
| cetuximab and panitumumabCetuximab and panitumumab for previously untreated metastatic colorectal cancer | TA439 | recommended | 2017-03 |
| trifluridine tipiracilTrifluridine–tipiracil for previously treated metastatic colorectal cancer | TA405 | recommended | 2016-08 |
| regorafenibRegorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) | TA334 | terminated | 2015-02 |
| afliberceptAflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy | TA307 | not recommended | 2014-03 |
Showing the 12 most recent of 15.
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| oxaliplatinDBL OXALIPLATIN oxaliplatin concentrate for infusion vial 100mg/20mL | 2009 | 18 |
| raltitrexedTOMUDEX raltitrexed 2mg powder for injection vial | 1996 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 6 of 8 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.